Clinical Trials in Myositis: Where Do We Stand?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F21%3AN0000017" target="_blank" >RIV/00023728:_____/21:N0000017 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/21:10429239

Výsledek na webu

<a href="https://doi.org/10.1007/s40674-021-00180-3" target="_blank" >https://doi.org/10.1007/s40674-021-00180-3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s40674-021-00180-3" target="_blank" >10.1007/s40674-021-00180-3</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Clinical Trials in Myositis: Where Do We Stand?

Popis výsledku v původním jazyce

Purpose of review There are currently no universally accepted management guidelines for idiopathic inflammatory myopathies (IIM), with only limited clinical evidence available to guide treatment decisions. However, the situation is changing and the number of clinical trials is growing, thanks to the improvement in our understanding of disease pathogenesis and availability of novel immunomodulatory drugs. We provide an overview of completed and ongoing interventional clinical trials evaluating the efficacy of pharmacotherapy in various forms of adult IIMs. Recent findings Unfortunately, the results of many trials are not very encouraging and no single drug seems to be a real breakthrough, reflecting the difficulty associated with studying such rare and heterogenous group of diseases. Several drugs have proven good efficacy in certain IIM subgroups and there are promising novel candidates raising hope for the future. The efficacy of intravenous immunoglobulins in dermatomyositis has been clearly confirmed. Encouraging reports, albeit very preliminary, are coming from trials with JAK inhibitors. We eagerly await the results of a large clinical trial with abatacept or the cannabinoid receptor modulator lenabasum.

Název v anglickém jazyce

Clinical Trials in Myositis: Where Do We Stand?

Popis výsledku anglicky

Purpose of review There are currently no universally accepted management guidelines for idiopathic inflammatory myopathies (IIM), with only limited clinical evidence available to guide treatment decisions. However, the situation is changing and the number of clinical trials is growing, thanks to the improvement in our understanding of disease pathogenesis and availability of novel immunomodulatory drugs. We provide an overview of completed and ongoing interventional clinical trials evaluating the efficacy of pharmacotherapy in various forms of adult IIMs. Recent findings Unfortunately, the results of many trials are not very encouraging and no single drug seems to be a real breakthrough, reflecting the difficulty associated with studying such rare and heterogenous group of diseases. Several drugs have proven good efficacy in certain IIM subgroups and there are promising novel candidates raising hope for the future. The efficacy of intravenous immunoglobulins in dermatomyositis has been clearly confirmed. Encouraging reports, albeit very preliminary, are coming from trials with JAK inhibitors. We eagerly await the results of a large clinical trial with abatacept or the cannabinoid receptor modulator lenabasum.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30226 - Rheumatology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY

ISSN

2198-6002

e-ISSN

2198-6002

Svazek periodika

7

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

21

Strana od-do

222-242

Kód UT WoS článku

000655007600001

EID výsledku v databázi Scopus

—